Skip to content

Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy

Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02097446
Acronym
GUARDIX-FL
Enrollment
60
Registered
2014-03-27
Start date
Unknown
Completion date
2015-01-31
Last updated
2014-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genital Diseases, Female

Keywords

cystectomy

Brief summary

* Indication: Benign tumors of ovary(mature teratoma, mucinous cystadenoma, serous cystadenoma) * Intervention: Device ( Test group : Guardix-FL, Control group : Interceed) * Primary Outcome Measure : Anti-adhesion Rate * Assessment : Operative Day(Visit 2), Post-Operative Day+7days(Vist 3), Post-Operative Day+4weeks(Visit4), Post-Operative Day+5weeks(Visit 5)

Interventions

DEVICEGuardix-FL
DEVICEInterceed

Sponsors

Genewel Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
No

Inclusion criteria

1. The patients who sign the written informed consent 2. Women aged between 18 and 44 3. The patients who are able to participate in clinical trial during the period of study 4. The patients without abnormal figures at the screening laboratory examination 5. The patients expecting ovarian cystectomy for benign ovarian tumor(mature cystic teratoma, Mucinous cystadenoma, serous cystadenoma)

Exclusion criteria

1. The patients who took treatments with medical products which might be barrier to evaluate the effectiveness 2. The patients who took medicine like other anti-adhesion, absorbable hemostat and dose of steroid, immunosuppressants 3. The patients with severe drug allergy 4. The patients with infectious disease on abdominal or pelvic cavity 5. The patients who previously participated in another clinical trials within the past 30 days 6. The patients considered inappropriate for the study 7. The pregnant 8. The patients with severe renal disease 9. The patients with severe systemic diseases

Design outcomes

Primary

MeasureTime frameDescription
Anti-Adhesion RatePost-Operative Day+4weeks(Second - look)Adhesion yes or no

Secondary

MeasureTime frameDescription
ScorePost-Operative Day+4weeks(Second-look)Length of Adhesion x Grade of Adhesion

Countries

South Korea

Contacts

Primary ContactJun Ho Kim, Master
junho1012@idongsung.com82-10-6455-3455
Backup ContactDan Bee Youn, Bachelor's
yzz3675@idongsung.com82-10-5061-3675

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026